Danish pharmaceutical company Novo Nordisk announces that both subcutaneous and oral amycretin are now moving into Phase 3 studies for the treatment of obesity. The decision is based on completed clinical studies and positive feedback from regulatory authorities following Phase 2.

The Phase 3 program is planned to start in the first quarter of 2026 and is aimed at adults who are overweight or obese. Novo Nordisk expresses great confidence in the amycretin molecule and describes the decision as an important step forward. No financial details have been provided.